I
Immuneering Corp
NASDAQ:IMRX
Immuneering Corp
NASDAQ:IMRX
Price:
3.71
USD
-2.62%
Market Closed
Market Cap:
$240m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Immuneering Corp
NASDAQ:IMRX
|
US |
|
Flow Traders Ltd
AEX:FLOW
|
BM |
|
Oaktree Specialty Lending Corp
F:FFC0
|
US |
|
SQD.ai Strategies AG
F:IPOK
|
DE |
|
Sibanye Stillwater Ltd
F:47VS
|
ZA |
|
Vetropack Holding SA
F:VV2N
|
CH |
|
D
|
DTE Energy Co
F:DGY
|
US |
|
N
|
Nippon Steel Corp
XMUN:NPS
|
JP |
|
E
|
Everlast Minerals Ltd
ASX:EV8
|
AU |
|
FirstRand Ltd
F:FSRA
|
ZA |
|
Autoneum Holding AG
F:AN9
|
CH |
|
Y
|
Yancoal Australia Ltd
F:YA1
|
AU |
|
Information Planning Co Ltd
OTC:IPNAF
|
JP |
|
Mineralbrunnen Ueberkingen-Teinach GmbH & Co KgaA
F:MUT
|
DE |
|
Beneteau SA
F:3GD
|
FR |
|
O
|
Olin Corp
F:OLN
|
US |
|
S
|
Siemens AG
XMUN:SIE
|
DE |
Intrinsic Value
Not Available for IMRX
There is not enough data to reliably calculate the intrinsic value for Immuneering Corp.
Do our valuations actually work? See backtest results .
Alternatives to IMRX
Fundamental Analysis
What Immuneering Does
Immuneering Corp is a clinical-stage biopharmaceutical company that develops cancer medicines. It does not sell approved drugs at scale yet; instead, it is trying to turn its research into prescription therapies, especially oral small-molecule treatments aimed at tumors driven by the MAPK signaling pathway.
- Headquarters
- United States of America US
- Employees
- 53
- IPO date
- Jul 30, 2021
Financials
Efficiency
Earnings Waterfall
Immuneering Corp
Immuneering Corp
